ReShape Lifesciences (RSLS) stock price, revenue, and financials

ReShape Lifesciences market cap is $27.9 m, and annual revenue was $11.3 m in FY 2020

$27.9 M

RSLS Mkt cap, 07-May-2021

$11.3 M

ReShape Lifesciences Revenue FY, 2020
ReShape Lifesciences Gross profit (FY, 2020)6.3 M
ReShape Lifesciences Gross profit margin (FY, 2020), %55.4%
ReShape Lifesciences Net income (FY, 2020)-21.6 M
ReShape Lifesciences EBIT (FY, 2020)-12.5 M
ReShape Lifesciences Cash, 31-Dec-20203 M
ReShape Lifesciences EV38.6 M

ReShape Lifesciences Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

123.1k188.4k79.0k64.0k72.0k276.0k296.8k40.0k93.1k360.0k950.0k653.4k350.2k3.1m4.5m3.5m2.8m1.7m

Cost of goods sold

85.5k146.0k30.8k23.3k40.1k155.3k146.6k29.5k54.5k214.5k829.0k634.8k263.9k843.0k1.6m1.4m1.3m865.0k

Gross profit

37.6k42.4k48.2k40.7k31.9k120.7k150.1k10.5k38.6k145.5k121.0k18.6k86.3k2.2m2.9m2.1m1.5m837.0k

Gross profit Margin, %

31%23%61%64%44%44%51%26%41%40%13%3%25%73%64%60%54%49%

R&D expense

3.3m4.8m2.7m2.2m2.6m2.7m2.7m2.8m2.6m3.1m2.3m2.2m2.5m1.8m1.4m1.2m1.3m1.1m1.4m1.1m2.7m2.4m1.3m1.1m960.0k858.0k1.3m465.0k

General and administrative expense

2.1m2.4m2.8m2.5m3.0m3.6m3.4m3.2m3.9m4.3m3.3m4.7m4.9m4.3m6.1m5.6m3.4m5.9m5.6m4.6m10.0m6.7m6.4m5.4m6.8m5.4m1.5m831.0k

Operating expense total

5.4m7.1m5.5m4.8m5.6m6.3m6.1m6.0m6.6m7.4m5.6m7.0m7.4m6.1m7.6m6.8m4.6m7.1m6.9m5.7m12.7m36.3m7.6m6.5m14.3m7.7m5.6m3.8m

EBIT

(5.5m)(4.7m)(5.6m)(6.3m)(6.1m)(6.0m)(6.6m)(7.4m)(5.6m)(7.0m)(7.3m)(6.0m)(7.5m)(6.7m)(4.5m)(7.0m)(6.9m)(5.6m)(12.6m)(36.3m)(7.5m)(4.2m)(11.5m)(5.6m)(4.1m)(3.0m)

EBIT margin, %

(4457%)(2510%)(9292%)(9391%)(10475%)(2412%)(1505%)(17590%)(7387%)(1544%)(1328%)(5559%)(2154%)(138%)(258%)(160%)(146%)(176%)

Interest expense

164.3k167.8k143.6k229.3k263.7k261.1k247.6k565.5k

Interest income

1.1k2.3k1.6k2.6k3.2k2.2k1.4k1.2k1.0k746.0755.0867.0422.0157.01.7k1.8k1.5k100.0411.0263.0217.0

Pre tax profit

(12.6m)(36.5m)(7.5m)(4.5m)(16.5m)(28.8m)(4.3m)(3.7m)

Income tax expense

(1.4m)(1.2m)(531.1k)(586.0k)18.0k50.0k

Net Income

(5.6m)(7.3m)(5.6m)(5.0m)(5.8m)(6.6m)(6.3m)(6.3m)(6.7m)(7.5m)(5.7m)(7.2m)(7.4m)(4.2m)(7.4m)(5.0m)(6.5m)(7.4m)(6.8m)(10.0m)(11.2m)(35.3m)(7.0m)(4.5m)(15.9m)(28.8m)(4.3m)(3.6m)

ReShape Lifesciences Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

27.2m32.4m20.5m26.6m27.2m29.4m23.1m21.1m24.4m21.7m16.3m11.4m4.8m12.3m11.2m11.5m6.8m18.7m11.2m23.4m841.6k1.9m472.9k1.8m4.4m7.7m2.1m1.5m

Accounts Receivable

123.1k16.9k52.6k18.6k17.0k53.3k1.5k112.5k25.1k55.0k182.5k191.7k68.2k109.4k333.1k962.4k446.0k532.1k3.9m4.6m3.0m3.1m

Prepaid Expenses

912.6k716.4k776.0k634.8k558.4k584.1k607.2k570.3k618.7k353.1k241.6k463.0k338.4k232.6k873.5k462.1k371.4k401.8k536.9k252.5k723.1k919.5k601.1k2.5m2.3m1.8m2.0m2.0m

Inventories

1.0m1.1m1.6m1.3m1.4m1.2m1.1m895.3k915.5k1.1m1.3m1.4m1.9m2.0m2.1m1.7m1.4m1.6m2.8m2.1m1.1m1.0m1.3m1.2m1.3m2.1m

Current Assets

28.3m36.4m23.6m29.5m29.6m31.5m25.3m23.1m26.1m22.9m17.4m13.0m6.5m13.9m14.0m14.1m9.5m20.9m13.3m25.6m5.3m5.3m2.7m9.2m12.6m13.7m8.5m8.5m

PP&E

616.8k568.3k625.2k650.2k629.8k592.0k563.9k632.5k536.9k491.4k462.3k446.9k416.0k367.0k298.4k259.2k228.5k171.6k240.5k195.5k349.3k303.2k181.2k47.0k27.0k6.0k12.0k99.0k

Goodwill

6.4m6.4m27.2m

Total Assets

29.1m37.0m24.6m30.5m30.7m33.2m26.9m24.7m27.6m24.4m18.9m14.3m7.9m15.0m14.9m15.0m10.6m21.7m42.5m55.2m78.6m50.5m47.1m47.4m43.7m44.2m37.6m37.1m

Accounts Payable

122.4k261.3k262.6k98.8k292.7k449.2k227.4k180.2k274.0k187.4k51.6k47.5k447.2k195.8k261.4k357.0k680.8k533.6k1.1m706.5k2.9m4.2m4.4m7.6m9.9m3.9m3.8m4.1m

Short-term debt

1.7m2.3m189.3k1.0m2.0m4.0m4.0m7.0m4.0m4.0m4.0m2.0m997.8k1.2k44.8k3.3m4.9m

Current Liabilities

4.7m6.3m4.9m4.7m6.3m8.8m8.3m8.4m8.4m8.8m8.4m7.0m6.5m3.7m9.4m10.3m8.0m3.7m4.5m4.1m8.8m8.7m8.8m11.8m12.2m11.7m10.8m12.3m

Long-term debt

4.0m3.4m4.5m9.9m9.9m10.1m9.1m3.8m1.9m932.1k700.0k626.0k552.0k3.2m3.8m

Total Debt

5.6m5.7m4.7m10.9m11.9m14.1m13.1m10.8m5.9m4.9m4.0m2.0m997.8k1.2k44.8k700.0k626.0k552.0k6.5m8.7m

Total Liabilities

8.6m9.7m9.4m13.3m13.9m14.5m13.0m12.3m10.3m9.7m8.4m7.0m6.5m7.3m16.1m18.6m9.4m3.8m4.5m4.1m12.7m11.4m11.0m18.9m30.3m59.8m16.0m18.0m

Common Stock

279.0k367.5k367.6k396.7k415.6k556.2k556.2k586.2k672.0k688.8k688.9k744.0k744.0k1.1m85.0k132.2k744.1k69.1k83.0k122.1k309.6k36.1k6.0k77.0k285.0k5.0k

Preferred Stock

10.0k

Additional Paid-in Capital

181.5m195.6m197.1m204.1m209.5m224.9m226.4m231.2m249.2m254.2m255.7m265.8m267.3m277.5m283.6m286.2m296.9m326.2m353.1m376.1m411.6m424.2m428.3m451.9m452.5m452.5m519.1m520.3m

Retained Earnings

(161.4m)(168.7m)(182.3m)(187.3m)(193.1m)(206.8m)(213.1m)(219.4m)(232.7m)(240.2m)(245.9m)(259.3m)(266.7m)(270.8m)(285.0m)(290.0m)(296.5m)(308.3m)(315.1m)(325.1m)(346.0m)(385.1m)(392.2m)(423.5m)(439.4m)(468.1m)(497.5m)(501.1m)

Total Equity

20.4m27.3m15.1m17.2m16.8m18.7m13.8m12.4m17.2m14.7m10.5m7.3m1.4m7.7m(1.3m)(3.6m)1.2m17.9m38.0m51.0m65.9m39.1m36.0m28.6m13.4m(15.7m)21.6m19.2m

Financial Leverage

1.4 x1.4 x1.6 x1.8 x1.8 x1.8 x1.9 x2 x1.6 x1.7 x1.8 x2 x5.5 x1.9 x-11.8 x-4.2 x9.2 x1.2 x1.1 x1.1 x1.2 x1.3 x1.3 x1.7 x3.3 x-2.8 x1.7 x1.9 x

ReShape Lifesciences Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(10.6m)(17.9m)(5.6m)(10.6m)(16.4m)(6.6m)(12.9m)(19.2m)(6.7m)(14.2m)(19.9m)(7.2m)(14.6m)(18.7m)(7.4m)(12.4m)(18.9m)(7.4m)(14.2m)(24.2m)(11.2m)(46.5m)(53.5m)(4.5m)(20.4m)(49.1m)(4.3m)(7.9m)

Depreciation and Amortization

143.3k223.6k68.0k125.6k177.6k42.1k81.6k124.4k47.5k95.0k141.9k48.7k97.4k146.3k39.4k78.7k109.4k29.1k68.8k158.6k764.5k1.5m2.3m433.0k863.0k1.3m4.0k838.0k

Accounts Receivable

(123.1k)(16.9k)(52.6k)(10.2k)(8.6k)(8.9k)17.7k17.7k17.7k1.3k(109.7k)(22.3k)2.9k(124.6k)(133.8k)75.5k34.3k(189.4k)(473.7k)42.6k(43.5k)(3.0m)(3.7m)(2.3m)848.0k1.0m

Inventories

65.9k(19.4k)(542.7k)(64.9k)(87.0k)98.9k36.8k232.7k212.4k(145.8k)(303.9k)(395.5k)(181.9k)(271.5k)(447.5k)86.7k272.3k(257.2k)21.8k716.1k1.8m(40.0k)(363.0k)(204.0k)60.0k(950.0k)

Accounts Payable

198.7k323.6k(187.6k)(431.7k)(271.2k)87.8k(127.9k)102.9k146.7k60.0k(75.8k)(347.2k)52.5k(198.9k)89.4k184.9k508.8k(778.1k)(388.6k)(788.2k)1.8m3.1m3.3m1.1m3.4m3.0m(865.0k)(958.0k)

Cash From Operating Activities

(9.3m)(14.5m)(7.4m)(12.5m)(17.0m)(5.0m)(10.2m)(14.1m)(5.6m)(10.6m)(15.0m)(5.6m)(11.2m)(17.2m)(6.9m)(12.5m)(17.1m)(4.4m)(10.1m)(15.7m)(9.3m)(15.8m)(20.4m)(5.7m)(8.6m)(12.9m)(3.2m)(5.8m)

Purchases of PP&E

(221.3k)(239.0k)(48.1k)(51.8k)(51.8k)(3.6k)(20.9k)(410.5k)(7.3k)(9.3k)(27.1k)(18.7k)(36.5k)(37.3k)(11.5k)(11.5k)(11.5k)(5.3k)(108.6k)(7.0k)(7.0k)

Capital Expenditures

(82.0k)

Cash From Investing Activities

6.1m3.1m(48.1k)(51.8k)948.2k(3.6k)(20.9k)(410.5k)(7.3k)(9.3k)(27.1k)(18.7k)(36.5k)(37.3k)(11.5k)(11.5k)(11.5k)(1.9m)(2.0m)(7.0k)(7.0k)(82.0k)

Short-term Borrowings

(367.2k)(367.2k)(563.5k)(752.8k)(752.8k)(1.0m)(2.0m)(1.0m)(2.0m)(3.0m)(1.0m)(2.0m)(3.0m)

Long-term Borrowings

(333.3k)(333.3k)(333.3k)(333.3k)

Cash From Financing Activities

(399.8k)13.0m(550.4k)10.6m14.8m12.1m11.0m13.4m6.7m9.0m8.0m5.5m4.4m17.9m10.1m16.1m16.0m19.8m19.8m37.8m7.5m10.7m2.0m7.4m15.1m2.5m4.5m

Net Change in Cash

(3.6m)1.6m(8.0m)(1.9m)(1.3m)7.1m778.8k(1.2m)1.1m(1.6m)(7.0m)(186.9k)(6.8m)641.8k3.2m3.6m(1.1m)15.4m7.9m20.1m(9.3m)(8.3m)(9.7m)(3.7m)(1.2m)2.2m(818.0k)(1.4m)

Interest Paid

264.3k359.5k82.5k(213.0k)(417.4k)200.0k397.6k574.7k133.6k249.4k344.7k53.6k87.6k601.2k163.2k163.2k169.3k

Free Cash Flow

(5.9m)

ReShape Lifesciences Ratios

USDQ2, 2011

Financial Leverage

1.4 x